<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03999125</url>
  </required_header>
  <id_info>
    <org_study_id>SudhalkarEH</org_study_id>
    <nct_id>NCT03999125</nct_id>
  </id_info>
  <brief_title>Anti-VEGF Therapy Versus Dexamethasone Implant for DME</brief_title>
  <official_title>Anti-VEGF Therapy Versus Dexamethasone Implant for Treatment Naive Diabetic Macular Edema: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sudhalkar Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sudhalkar Eye Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We look at a randomized comparative study of 2 FDA approved anti-VEGF agents(aflibercept and&#xD;
      ranibizumab) and see how they compare against the dexamethasone implant for phakic as well as&#xD;
      pseudophakic eyes with treatment naive diabetic macular edema in terms of efficacy and safety&#xD;
      over two years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, partially masked, observational/interventional trial looking at the efficacy&#xD;
      and safety of 2 FDA approved anti-VEGF agents vis-a-vis the dexamethasone implant as primary&#xD;
      therapy for treatment naive diabetic macular edema in phakic as well as pseudophakic&#xD;
      patients.&#xD;
&#xD;
      Patients with treatment naive clinically significant macular edema will be randomized to&#xD;
      receive one of the aforementioned therapies in a 1:1:1 distribution. Primary inclusion&#xD;
      criteria are :&#xD;
&#xD;
      Well controlled diabetes(HbA1c&lt;7%) and co-morbidities. Central Subfield Thickness of 300&#xD;
      microns or greater BCVA &lt; or equal to 6/12.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
      Contraindications to the aforementioned drugs Confounding Ocular co-morbidities that can&#xD;
      affect visual assessment(except Cataract Grade II or less as per the LOCS III classification)&#xD;
      Refusal for enrolment&#xD;
&#xD;
      A comprehensive ocular and systemic examination will be performed along with fundus&#xD;
      fluorescein angiography, optical coherence tomography and intraocular pressure measurements&#xD;
      with the Goldmann Applanation Tonometer. The BCVA will be recorded using Snellen's chart&#xD;
&#xD;
      Intravitreal injections will be administered using a standardized technique and under strict&#xD;
      asepsis. No postoperative antibiotics will be given.&#xD;
&#xD;
      Patients will be followed on postoperative days 1, 7 and then monthly for 2 years.&#xD;
&#xD;
      At each visit, the BCVA, IOP, ocular exam and OCT scans will be performed at each visit.&#xD;
&#xD;
      Patients will be treated as per the guidelines laid out for the treat and extend study. For&#xD;
      the dexamethasone implant, re-injections will be allowed first 3 months after the first&#xD;
      injection.&#xD;
&#xD;
      Switch therapy is permissible for anti-VEGF agents after 6 months; first to the other&#xD;
      anti-VEGF(for 6 more injections) and then to the dexamethasone implant. Rescue Laser therapy&#xD;
      is as per physician's description.&#xD;
&#xD;
      Primary outcome measure: The BCVA in each group from baseline to final follow-up at 2 years.&#xD;
&#xD;
      Secondary outcome measure: Change in CST from baseline to years, the number of injections&#xD;
      required per group and the complications, if any.&#xD;
&#xD;
      Statistical Analysis will include demographic descriptions, the Shapiro Wilk test to look for&#xD;
      normality of distribution, multiple measures ANOVA test, Fisher's exact test, Chi-Square test&#xD;
      and paired and unpaired t-test wherever appropriate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2019</start_date>
  <completion_date type="Anticipated">June 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel, multi-arm trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>2 years</time_frame>
    <description>BCVA measured at baseline and final follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central Subfield Thickness</measure>
    <time_frame>2 years</time_frame>
    <description>Change in CST over 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>2 years</time_frame>
    <description>Complications in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Injection Count</measure>
    <time_frame>2 years</time_frame>
    <description>Number of injections in each group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Clinically Significant Macular Edema Due to Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aflibercept intravitreal injection for CSME</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ranibizumab Intravitreal Injection for CSME</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexamethasone Implant for CSME</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept,</intervention_name>
    <description>Primary therapy will be with Aflibercept. If the edema does not respond to the intervention, the patient will be treated with Ranibizumab, Dexamethasone Implant or Laser.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Ranibizumab</other_name>
    <other_name>Dexamethasone Implant, Laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab Injection</intervention_name>
    <description>Primary therapy will be with ranibizumab. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Dexamethasone Implant or Laser.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Dexamethasone Implant, Aflibercept, Laser</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex Drug Implant Product</intervention_name>
    <description>Primary therapy will be with Ozurdex. If the edema does not respond to the intervention, the patient will be treated with Alfibercept, Ranibizumab or Laser</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Well controlled diabetes(HbA1c&lt;7%) and co-morbidities. Central Subfield Thickness of&#xD;
             300 microns or greater BCVA &lt; or equal to 6/12.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to the aforementioned drugs Confounding Ocular co-morbidities that&#xD;
             can affect visual assessment(except Cataract Grade II or less as per the LOCS III&#xD;
             classification) Macular ischemia or proliferative Disease Refusal for enrolment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alphavision Augenzentrum</name>
      <address>
        <city>Bremerhaven</city>
        <state>Bremen</state>
        <zip>27568</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Alper Bilgic, MS</last_name>
      <phone>+491731505937</phone>
    </contact>
    <contact_backup>
      <last_name>Aditya Sudhalkar, MS</last_name>
      <phone>+919909917561</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sudhalkar Eye Hospital</investigator_affiliation>
    <investigator_full_name>Aditya Sudhalkar</investigator_full_name>
    <investigator_title>Consultant Vitreoretinal Surgeon</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Aflibercept</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All details of FFA, OCT, BCVA and IOP</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Upon completion of study</ipd_time_frame>
    <ipd_access_criteria>Will be provided only to Ophthalmologists</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

